BeiGene
ONC
364.02
+1.24
+0.34%
BeiGene
US · ONC
#538 by market cap
Listed 2016
364.02
+1.24
+0.34%
Live - 5344 symbols - heartbeat 113s ago
· 2026-10-08 05:10
Pre-market
353.40
-2.92%
After-hours
364.16
+0.04%
Overnight
353.82
-2.80%
- Market cap
- 41.39B
- P/E (TTM)i
- 64.43
- P/Bi
- 8.00
- EPSi
- 2.53
- Div yieldi
- 0.00%
- 52W posi
- 84%
Reader sentiment
Are you bullish or bearish on ONC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.1 percentage points.
Institutional ownership
- Held by institutions
- 77.51% +1.13pp
- Institutions
- 587 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund40.87%
Public Company17.83%
Hedge Fund10.69%
VC/PE Fund5.40%
Individual/Insider4.10%
Sovereign Wealth Fund1.26%
Private Company0.95%
Government Pension Fund0.40%
Other18.41%
Top holders as of 2025-12-31
Amgen Inc.
16.66% · 18.94M sh
Baker Bros. Advisors LP
7.77% · 8.84M sh
Capital Research
7.48% · 8.50M sh
PRIMECAP Management Company
4.41% · 5.01M sh
Hillhouse Capital Management, Ltd.
3.73% · 4.24M sh
John Oyler
3.12% · 3.54M sh
BlackRock
2.82% · 3.20M sh
China Asset Management Co., Ltd.
2.62% · 2.98M sh
Vanguard Capital Management, LLC
2.37% · 2.69M sh
FMR
2.16% · 2.45M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 31 sells
| Name | Role | Stake |
|---|---|---|
| Amgen Inc. | -- | 16.66% |
| John Oyler | Chairperson & CEO | 3.12% |
| Xiaodong Wang | Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder | 0.63% |
| Wang Lai | Global Head of R&D | 0.15% |
| Xiaobin Wu | President | 0.05% |
| Chan Lee | General Counsel & Senior VP | 0.02% |
| Felix Baker | Non-Executive Director | 0.02% |
| Michael Goller | Independent Non-Executive Director & Member of the Scientific Advisory Committee | 0.02% |
| Ranjeev Krishana | Lead Independent Director | 0.02% |
| Julia A. Wang | Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Chan Lee | General Counsel & Senior VP | Automatic Disposition | -1,115 | $375.00 |
| 2026-09-27 | Xiaodong Wang | Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder | Derivative Exercise and Sale | -31,028 | $36.90–367.23 |
| 2026-09-07 | Xiaodong Wang | Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder | Automatic Disposition | -7,260 | $345.38–348.01 |
| 2026-09-07 | Xiaodong Wang | Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder | Derivative Exercise and Sale | -31,027 | $36.90–351.25 |
| 2026-08-31 | Titus Ball | Vice President & Chief Accounting Officer | Open Market Disposition | -132 | $355.86 |
| 2026-08-24 | Corazon Sanders | Independent Non-Executive Director & Member of Scientific Advisory Committee | Intent to Sell (Form 144) | -2,075 | $380.00 |
| 2026-08-24 | Xiaobin Wu | President | Automatic Disposition | -280 | $380.00 |
| 2026-08-11 | John Oyler | Chairperson & CEO | Automatic Disposition | -240,810 | $350.00–367.00 |
| 2026-08-10 | Chan Lee | General Counsel & Senior VP | Derivative Exercise and Sale | -2,666 | $159.03–360.00 |
| 2026-08-09 | John Oyler | Chairperson & CEO | Intent to Sell (Form 144) | -240,810 | $348.27 |
| 2026-08-02 | Aaron Rosenberg | CFO & Principal Financial Officer | Open Market Disposition | -1,157 | $312.72 |
| 2026-07-29 | Chan Lee | General Counsel & Senior VP | Open Market Disposition | -1,044 | $323.69 |
| 2026-07-21 | Chan Lee | General Counsel & Senior VP | Derivative Exercise and Sale | -1,669 | $159.03–325.00 |
| 2026-07-20 | John Oyler | Chairperson & CEO | Automatic Disposition | -75,723 | $310.08–320.06 |
| 2026-07-19 | John Oyler | Chairperson & CEO | Derivative Exercise and Sale | -33,990 | $119.96–318.30 |
| 2026-07-13 | John Oyler | Chairperson & CEO | Automatic Disposition | -12,261 | $303.07–303.93 |
| 2026-07-09 | John Oyler | Chairperson & CEO | Intent to Sell (Form 144) | -150,000 | $302.83 |
| 2026-07-07 | Chan Lee | General Counsel & Senior VP | Derivative Exercise and Sale | -664 | $159.03–302.46 |
| 2026-06-22 | John Oyler | Chairperson & CEO | Open Market Disposition | -3,410 | $273.30–275.10 |
| 2026-06-22 | Wang Lai | Global Head of R&D | Open Market Disposition | -1,068 | $276.74 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:10:03 · For reference only, not investment advice and not tailored to your situation.